Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Early use of effective therapies may improve diabetes outcomes
Última actualización 13 de junio de 2026
Key finding
HbA1c decreased by 0.10% (Mean ± SD: -0.10 ± 0.46)
This study evaluated the cost-effectiveness of various glucose-lowering agents in type 2 diabetes patients, finding significant reductions in HbA1c levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the cost-effectiveness of various glucose-lowering agents in type 2 diabetes patients, finding significant reductions in HbA1c levels.
Clinical relevance
Understanding the effectiveness of various glucose-lowering agents is crucial for clinicians to make informed treatment decisions. By optimizing medication choices, healthcare providers can improve patient outcomes, reduce complications associated with diabetes, and potentially lower healthcare costs.
Keep in mind
Effectiveness of some interventions was unclear. Limited generalizability due to the modeling approach. Potential unmeasured confounders affecting outcomes.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Meredith H, Alice M, William JV. Modeling Analysis of Treatment Pathways for Type 2 Diabetes in the US. Diabetes Therapy. 2026. doi:10.1007/s13300-026-01846-8
Efectos Principales
HbA1c decreased by 2.37% with the most effective intervention.
HbA1c decreased by 1.86% with another intervention.
HbA1c decreased by 1.12% with a different treatment.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin and BMI, Estimated glomerular filtration rate, HDL cholesterol, and 4 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- BMI
- Estimated glomerular filtration rate
- HDL cholesterol
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
7
Evidence pairs
7
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
7
Evidence pairs
784
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 7 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Metformin Therapies and HbA1c
Evidencia relacionada
Relación de evidencia
Metformin Therapies and Body Mass Index
Guardar evidencia
Relación de evidencia
Metformin Therapies and Adipokine and Angiogenic Markers
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Estimated glomerular filtration rate
Metformin → Estimated glomerular filtration rate
Metformin → Estimated glomerular filtration rate
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 11 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- HbA1c decreased by 2.37% with the most effective intervention.
- HbA1c decreased by 1.86% with another intervention.
- HbA1c decreased by 1.12% with a different treatment.
Tener en Cuenta
- Effectiveness of some interventions was unclear.
- Limited generalizability due to the modeling approach.
- Potential unmeasured confounders affecting outcomes.
Entre Líneas
- Effectiveness of some interventions was unclear.
- Limited generalizability due to the modeling approach.
- Potential unmeasured confounders affecting outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, Metformin Therapies and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Estudios de apoyo: Basado en 11 estudios
View evidenceMedications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 11 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 3 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
11 studies
intervention_hubContributes to Metformin Therapies evidence base.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
3 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
11 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies on Metformin
Intervention: Metformin
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve HbA1c?
Strong Evidence
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.2 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body mass index?
Strong Evidence
Metformin Therapies appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve blood pressure?
Moderate Evidence
Metformin Therapies appears to improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Metformin Therapies improve adipokine and angiogenic markers?
Moderate Evidence
Metformin Therapies may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
LDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsPremeal metformin improves postmeal glucose control in diabetes.Canagliflozin with metformin reduces cardiovascular risk in T2DMCombined Antioxidant and Prebiotic Supplementation Improves T2 Diabetes Outcomes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.